This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodriguez, C. Articles by Theillet, C. Search for Related Content PubMed PubMed Citation Articles by Rodriguez, C. Articles by Theillet, C.

Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome

¹ Génotype et Phénotypes Tumoraux E 229 INSERM, Centre Val d’Aurelle, Montpellier, France; ² Cancer Research UK/Wellcome Institute, Cambridge, United Kingdom

DNA amplification at band q13 of chromosome 11 is common in breast cancer, and CCND1 and EMS1 remain the strongest candidate genes. However, amplification patterns are consistent with the existence of four cores of amplification, suggesting the involvement of additional genes. Here we present evidence strongly suggesting the involvement of the recently characterized EMSY gene in the formation of the telomeric amplicon. EMSY maps at 11q13.5, 100 kb centromeric to the GARP gene, which has been mapped within the core of the distal amplicon. The EMSY protein was shown to interact with BRCA2 and has a role in chromatin remodeling. This makes EMSY a strong candidate oncogene for the 11q13.5 amplicon. DNA amplification was studied in a total of 940 primary breast tumors and 39 breast cancer cell lines. Amplification profiles were consistent with the EMSY-GARP locus being amplified independently of CCND1 and/or EMS1. EMSY RNA expression levels were studied along with those of five other genes located at 11q13.5 by real-time quantitative PCR in the 39 cell lines and a subset of 65 tumors. EMSY overexpression correlated strongly with DNA amplification in both primary tumors and cell lines. In a subset of 296 patients, EMSY amplification was found by both uni- and multivariate analyses to correlate with shortened disease-free survival. These data indicate that EMSY is a strong candidate oncogene for the 11q13.5 amplicon.

This article has been cited by other articles:

				D S P Tan, C Marchio, and J S Reis-Filho Hereditary breast cancer: from molecular pathology to tailored therapies J. Clin. Pathol., October 1, 2008; 61(10): 1073 - 1082. [Abstract] [Full Text] [PDF]

				S. El Messaoudi, E. Fabbrizio, C. Rodriguez, P. Chuchana, L. Fauquier, D. Cheng, C. Theillet, L. Vandel, M. T. Bedford, and C. Sardet Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene PNAS, September 5, 2006; 103(36): 13351 - 13356. [Abstract] [Full Text] [PDF]

				J. Yao, S. Weremowicz, B. Feng, R. C. Gentleman, J. R. Marks, R. Gelman, C. Brennan, and K. Polyak Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res., April 15, 2006; 66(8): 4065 - 4078. [Abstract] [Full Text] [PDF]

				A. Raouf, L. Brown, N. Vrcelj, K. To, W. Kwok, D. Huntsman, and C. J. Eaves Genomic Instability of Human Mammary Epithelial Cells Overexpressing a Truncated Form of EMSY J Natl Cancer Inst, September 7, 2005; 97(17): 1302 - 1306. [Abstract] [Full Text] [PDF]